InvestorsHub Logo
Followers 2
Posts 436
Boards Moderated 0
Alias Born 01/14/2014

Re: None

Saturday, 07/15/2017 4:41:42 AM

Saturday, July 15, 2017 4:41:42 AM

Post# of 807
TTPS://www.youtube.com/watch?v=Oyv5QogoJhw

Novartis CAR-T programmes
Candidate Target antigen *Indication Development
CTL019 CD19 B-ALL Pivotal phase II (ELIANA trial)
CTL019 CD19 DLBCL Pivotal phase II (JULIET trial)
BCMA MM Phase I/II
CTL119 CD19 CLL Human pilot
“CART22� CD22 B-ALL Terminated in phase I (June 2017)
Multiple Pre-clinical/phase I

HTTPS://clinicaltrials.gov/ct2/show/NCT02546167